Dr. Bradford Wood is Chief of IR and directs a multi-disciplinary team (NIH Center for Interventional Oncology) that develops and translates devices, software, and navigation approaches for cancer patients via novel local and regional minimally-invasive image-guided therapies..
Dr. Wood is the founding Director of the NIH Center for Interventional Oncology, which translates technologies and paradigms for first-in-human treatments for cancer and cultivates interventional radiology applications within a multi-disciplinary framework, to apply biomedical engineering to meet real-life unmet clinical needs.
His team's achievements include helping to pioneer several technologies from concept to bench to patient, and was first-in-human; for the following device/drug combinations: prostate cancer MRI/TRUS fusion biopsy and ablation, image-able iodinated drug eluting beads for chemoembolization of liver tumors, kidney cancer ablation, adrenal cancer ablation, heat-deployed nanoparticle chemotherapy with thermal ablation for liver cancer, electromagnetic tracking for fusion of ultrasound to CT, MR, and PET, and fusion for biopsy and ablation.
His team's research relies upon multi-disciplinary team science within multiple institutes and international public-private partnerships. His team has mentored hundreds of students, fellows, physicians, nurses, and scientists. His teams have authored 50 patents, books on radiology and interventional urology, and co-authored more than 500 peer-reviewed manuscripts, with an H-index of 84, including JAMA, NEJM, Nature Communications, Science, Lancet, Blood, Chest, Cancer, JCO, CCR, JAMA Oncology, Hepatology, Medical Physics, and Scientific Reports.
Teamwork breeds team success.
See his Intramural Research Program bio page.
Harmon SA, Sanford TH, Xu S, Turkbey EB, Roth H, Xu Z, Yang D, Myronenko A, Anderson V, Amalou A, Blain M, Kassin M, Long D, Varble N, Walker SM, Bagci U, Ierardi AM, Stellato E, Plensich GG, Franceschelli G, Girlando C, Irmici G, Labella D, Hammoud D, Malayeri A, Jones E, Summers RM, Choyke PL, Xu D, Flores M, Tamura K, Obinata H, Mori H, Patella F, Cariati M, Carrafiello G, An P, Wood BJ, Turkbey B. Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nat Commun. 2020;11(1):4080.
Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917-928.
Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ: Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999-1007.
Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-7.
Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011 Oct;186(4):1281-5
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 07/07/2021